secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001477932-24-001451
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M
---------------------------------------------------------------

- Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.
- Cash & equivalents $20.7M at Dec 31, 2023 (vs $10.9M end of 2022); received $13.0M milestone from Heska in Dec 2023.
- Sold kits for over 58,000 Nu.Q Vet Cancer Tests in 2023; new partnerships including Fujifilm Vet Systems; in-house test via Heska/Antech coming soon.
- Nu.Q NETs pillar advanced with FDA regulatory pathway; Capture-PCR breakthrough presented at ESMO 2023.
- Conference call March 26, 2024 at 8:30 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/0001477932-24-001451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-001451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer